The immunochemistry analyzer market is expected to register a CAGR of 16% during the forecast period, up from USD 14.2 Billion in 2021, to reach a valuation of USD 72.69 Billion by 2032.
The Immunochemistry analyzer market is anticipated to show promising growth prospects during the forecasted period due to increased demand for immunochemistry analyzers to diagnose and identify microorganism-based illnesses.
| Attributes | Details |
|---|---|
| Immunochemistry Analyzer Market Value (2021) | USD 14.2 Billion |
| Immunochemistry Analyzer Market Value (2032) | USD 72.69 Billion |
| CAGR (2022 to 2032) | 16% |
Sales of immunochemistry analyzers are expected to grow due to the rising demand for immunochemistry analyzers to diagnose and detect microorganism-based illnesses and disorders, together with the increasing requirement for managing and suppressing the incidence of major diseases.
This is driving the expansion of the immunochemistry analyzers market.
Immunochemistry analyzers automatically run tests on samples from patients to detect any number of biologically active substances. Another factor driving the demand for immunochemistry analyzer is its usage in infectious disease testing, cancer, cardiac, and autoimmune diseases.
Some of the critical immunochemistry analyzer market trends promoting the demand for immunochemistry analyzers include the rise in demand for improved diagnostic equipment, as well as the rise in automation and integration trends, has resulted in the creation of novel products, which are likely to provide substantial growth opportunities for the immunochemistry analyzers market from 2022 to 2032.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The increased demand for immunochemistry analyzers to diagnose and identify microorganism-based illnesses is one of the significant reasons likely to drive the growth and demand for immunochemistry analyzers.
Furthermore, the rapid rise in the need for controlling and suppressing the occurrence of significant diseases, as well as the rising demand for immunochemistry analyzers the incidence of chronic disease conditions such as cancer and autoimmune disorders, are expected to drive growth in the global immunochemistry analyzers market from 2022 to 2032.
Similarly, the growing elderly population, quick changes in lifestyle, and increased smoking and drinking habits are expected to drive the immunochemistry analyzer market expansion.
Additionally, the increased demand for automated and portable immunochemistry systems is projected to function as a driver for the immunochemistry analyzer market.
North America had the highest revenue share of 38% in the immunochemistry analyzers market, followed by Europe.
The most significant immunochemistry analyzer market share of North America was primarily ascribed to the commercial availability of sophisticated technology items and the high adoption rate of these products. Furthermore, significant players in the country generate revenue for the United States.
From 2022 to 2032, the Asia Pacific region immunochemistry analyzers market is predicted to develop quickly, with a CAGR of 7.0%. Japan is one of the leading countries in terms of technological advancements and the increased use of immunochemistry analyzers for various applications. Furthermore, China is a significant contributor to this immunochemistry analyzers market expansion.
The region's thriving medical tourism business is likely to stimulate demand for immunochemistry analyzers in countries such as Japan, China, Malaysia, Thailand, and India. The availability of trained labor at a low cost and modern manufacturing infrastructure is causing major pharmaceutical companies to relocate their manufacturing operations to the Asia Pacific area.
As a result, the constantly expanding number of industrial facilities in the area is fueling the growth of the Asia Pacific immunochemistry analyzers market.
The immunochemistry analyzer market is entirely fragmented with leading brands, such as Siemens, Abbott Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc. and F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc. bought Mesa Biotech, a private point-of-care molecular diagnostic startup, in February 2021.
Abbott got the CE Mark for their Panbio COVID-19 Ag Rapid Test Device for the asymptomatic detection of the SARS-CoV-2 virus in January 2021. It also has self-swabbing capabilities.
Beckman Coulter, a Danaher (USA) business, will offer the first high-quality and throughput test for COVID-19 antigen diagnosis, named Access SARS-CoV-2 Antigen assay, in the USA in December 2020.
Thermo Fisher Scientific will introduce its EliA SARS-CoV-2-Sp1 IgG test and OmniPATH COVID-19 Total Antibody ELISA test for the detection of COVID-19 antibodies in October 2020.
| Report Attributes | Details |
|---|---|
| Growth rate | CAGR of 16% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Product, application, region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Siemens; Abbott Diagnostics; Beckman Coulter; Ortho Clinical Diagnostics; Thermo Fisher Scientific Inc. and F. Hoffmann-La Roche Ltd. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The Immunochemistry analyzer market is likely to register a CAGR of 16% during the forecast period.
Key players holding substantial Immunochemistry analyzer market share include
As per the analysis, the Immunochemistry analyzer market share is likely to be USD 72.69 Billion by 2032.
Demand for immunochemistry analyzer is likely to rise due to increasing demand for improved diagnostic equipment, as well as the rise in automation and integration trends.
| Estimated Market Size in 2024 | USD 3.5 billion |
|---|---|
| Projected Market Value in 2034 | USD 7.4 billion |
| Value-based CAGR (2024 to 2034) | 7.8% |
| Projected Forecast Value (2023) | USD 113.54 billion |
|---|---|
| Projected Forecast Value (2033) | USD 206.96 billion |
| Growth rate (2023 to 2033) | 6.2% CAGR |
| Market Value (2021) | USD 2.08 Billion |
|---|---|
| Market Value (2032) | USD 4.5 Billion |
| Market CAGR (2022 to 2032) | 7.25% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Immunochemistry Analyzer Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
